Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

INNATE LYMPHOID CELLS

ILC2s in cancer: context matters

Nature Immunology volume 22, pages 804–806 (2021)Cite this article

Subjects

The role of type 2 innate lymphoid cells (ILC2s) in cancer is currently under substantial scrutiny. New data show that ILC2s producing the proinflammatory cytokine GM-CSF coordinate eosinophils’ recruitment and activation to enhance antitumor responses

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ILC2s drive the eosinophil antitumor response against melanoma.

Servier Medical Art, licensed under a Creative Commons Attribution 3.0 Unported License.

References

  1. Jacquelot, N. et al. Nat. Immunol. https://doi.org/10.1038/s41590-021-00943-z (2012).

    Article  Google Scholar 

  2. Monticelli, L. A. et al. Nat. Immunol. 12, 1045–1054 (2011).

    Article  Google Scholar 

  3. Bie, Q. et al. J. Immunol. Res. 2014, 923135 (2014).

    Article  Google Scholar 

  4. Trabanelli, S., Chevalier, M. F., Derré, L. & Jandus, C. Semin. Immunol. 41, 101276 (2019).

    Article  CAS  Google Scholar 

  5. Trabanelli, S. et al. Nat. Commun. 8, 593 (2017).

    Article  Google Scholar 

  6. Chevalier, M. F. et al. J. Clin. Invest. 127, 2916–2929 (2017).

    Article  Google Scholar 

  7. Schuijs, M. J. et al. Nat. Immunol. 21, 998–1009 (2020).

    Article  CAS  Google Scholar 

  8. Long, A. et al. J. Immunol. 201, 3456–3464 (2018).

    Article  CAS  Google Scholar 

  9. Ikutani, M. et al. J. Immunol. 188, 703–713 (2012).

    Article  CAS  Google Scholar 

  10. Kim, J. et al. J. Immunol. 196, 2410–2423 (2016).

    Article  CAS  Google Scholar 

  11. Moral, J. A. et al. Nature 579, 130–135 (2020).

    Article  CAS  Google Scholar 

  12. Wang, S. et al. Cell Res. 30, 610–622 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UMR INSERM, 1231, Dijon, France

    Melanie Bruchard & Francois Ghiringhelli

  2. Centre Georges Francois Leclerc, Dijon, France

    Francois Ghiringhelli

  3. University of Burgundy-Franche Comté, Dijon, France

    Francois Ghiringhelli

Authors
  1. Melanie Bruchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francois Ghiringhelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francois Ghiringhelli.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bruchard, M., Ghiringhelli, F. ILC2s in cancer: context matters. Nat Immunol 22, 804–806 (2021). https://doi.org/10.1038/s41590-021-00945-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-021-00945-x

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer